Flamma SpA is proud to announce that Mr. Gian Paolo Negrisoli, Flamma CEO, has been granted Honorary Dalian Citizenship for his friendship to China and his contribution in promoting economic exchanges and cooperation through Flamma Honkai.
Chignolo D’Isola, Bergamo, Italy – November 21, 2019 – Flamma SpA (“Flamma”), a preeminent Contract Development and Manufacturing Organization (CDMO) that develops, manufactures, and commercializes small molecule Active Pharmaceutical Ingredients (APIs) for the pharmaceutical industry, is proud to announce that Mr. Gian Paolo Negrisoli, Flamma CEO, has been granted Honorary Dalian Citizenship for his friendship to China and his contribution in promoting economic exchanges and cooperation through Flamma Honkai. Negrisoli is the first Italian to receive such Award, the 145th in city history. Dalian, located in the Liaoning Province, has the largest multi-purpose port in Northeast China and has a population over 7 million people.
Part of the Flamma Group from 2011, Flamma Honkai is a 100% owned and managed facility. Flamma Honkai is part of the fully integrated supply chain (combining Italy, China, and the USA) that Flamma offers its customers.
Flamma Honkai, located in Songmudao Chemical Park, opened its new cGMP workshop, new R&D labs and new QC labs in June 2017. Flamma Honkai will begin construction of a state of the art facility on a new site in 2020 as it continues to be one of most reliable and qualified CDMOs in Asia.
Contact Flamma
Kenneth Drew, Ph.D., Sr. Director, North America Sales and Business Development 1-617-515-0975 ken.drew@flammagroup.com
About Flamma:
FLAMMA is a family owned & run, fully integrated CMO based in Bergamo (near Milan in Northern Italy) established in 1950.
FLAMMA is a company specialized in the cGMP manufacture of APIs, NCEs, RSMs, and advanced intermediates for the pharmaceutical industry. Flamma has particular expertise in high value chiral materials specifically amino acid related materials. Flamma also manufactures specialty compounds and advanced intermediates for the nutraceutical and cosmetic industries and has several generic products.
FLAMMA has four manufacturing facilities all with R&D labs- Italy (2), China, and the USA. Both cGMP Italian locations (Chignolo & Isso) are regularly inspected by the FDA and AIFA. Flamma Honkai, located in Dalian, China, has a new R&D building as well as a cGMP production plant. Flamma provides security when working in China with our 100% owned, self-managed facilities that deliver results without worry. Flamma reliably supplies materials directly to customers and/or delivers materials to its cGMP facilities in Italy in order to deliver the customer’s compound on-time and with the desired specifications. Flamma offers cost- effective services to customers looking for a trusted partner within China.
The recently acquired Flamma-delphia site located outside Philadelphia provides Flamma with the ability to service customers looking to keep materials in the USA for pre-clinical/early stage clinical development.
Being a fully integrated company allows Flamma to move your compounds quickly along their journey taking into consideration all aspects necessary for the success of your project.
Flamma can be of assistance for early stage pre-clinical development of small molecules as well as for large-scale commercial manufacturing. With a total reactor capacity of 450 m3 and over 550 employees, see why Flamma should be your next contract manufacturer. FLAMMA - THE THINKING CDMOTM.
For more information, please visit www.flammagroup.com
https://www.linkedin.com/company/flamma-spa/
https://twitter.com/flammagroup
https://www.facebook.com/TheFlammaGroup/
